Business Context and Reporting Period
This Form 8-K was filed by Pharmacyte Biotech, Inc. on October 10, 2017. The report discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors to fill a vacancy.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the compensation package for the newly appointed director:
- Quarterly Cash Retainer: $12,500 per calendar quarter.
- Annual Equity Grant: 500,000 shares of restricted common stock.
- Annual Option Grant: Option to purchase 500,000 shares.
- Option Exercise Price: $0.055 per share (based on fair market value on the grant date).
Material Changes
The primary material change reported is the appointment of Raymond C.F. Tong, M.D., to the Board of Directors on October 9, 2017. Dr. Tong was appointed to fill a vacancy created by the departure of certain board members and will serve as a member of the Audit Committee. The filing states the company is not aware of any transactions requiring disclosure under Item 404(a) of Regulation S-K regarding Dr. Tong.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks or contingencies. The document focuses solely on the execution of the Letter Agreement with Dr. Tong and the associated press release.
Investor Verification Checklist
- Verify the total number of shares outstanding to assess the dilution impact of the 500,000 annual share grants and options.
- Confirm the current fair market value of the common stock to evaluate the attractiveness of the $0.055 exercise price.
- Review the full text of the Letter Agreement (Exhibit 10.1) for any additional terms or conditions not summarized in the 8-K.
- Investigate the reasons for the "departure of certain members of the Board" mentioned as the cause for the vacancy.